Market Research Logo

Acute Coronary Syndrome - Pipeline Review, H1 2015

Acute Coronary Syndrome - Pipeline Review, H1 2015

Summary

Global Markets Direct’s, ‘Acute Coronary Syndrome - Pipeline Review, H1 2015’, provides an overview of the Acute Coronary Syndrome’s therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Acute Coronary Syndrome, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Acute Coronary Syndrome and special features on late-stage and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

  • The report provides a snapshot of the global therapeutic landscape of Acute Coronary Syndrome
  • The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved in the therapeutics development for Acute Coronary Syndrome and enlists all their major and minor projects
  • The report summarizes all the dormant and discontinued pipeline projects
  • A review of the Acute Coronary Syndrome products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
  • Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • A detailed assessment of monotherapy and combination therapy pipeline projects
  • Coverage of the Acute Coronary Syndrome pipeline on the basis of target, MoA, route of administration and molecule type
  • Latest news and deals relating related to pipeline products
Reasons to buy
  • Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Identify and understand important and diverse types of therapeutics under development for Acute Coronary Syndrome
  • Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
  • Devise corrective measures for pipeline projects by understanding Acute Coronary Syndrome pipeline depth and focus of Indication therapeutics
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline


Introduction
Global Markets Direct Report Coverage
Acute Coronary Syndrome Overview
Therapeutics Development
Pipeline Products for Acute Coronary Syndrome - Overview
Pipeline Products for Acute Coronary Syndrome - Comparative Analysis
Acute Coronary Syndrome - Therapeutics under Development by Companies
Acute Coronary Syndrome - Pipeline Products Glance
Late Stage Products
Clinical Stage Products
Early Stage Products
Acute Coronary Syndrome - Products under Development by Companies
Acute Coronary Syndrome - Companies Involved in Therapeutics Development
advanceCor GmbH
Arena Pharmaceuticals, Inc.
Artery Therapeutics, Inc.
AstraZeneca PLC
Athera Biotechnologies AB
Auspex Pharmaceuticals, Inc.
Bayer AG
Esperion Therapeutics, Inc.
GlaxoSmithKline Plc
Lee's Pharmaceutical Holdings Limited
MedImmune, LLC
Pfizer Inc.
The Medicines Company
Vitae Pharmaceuticals, Inc.
XOMA Corporation
Acute Coronary Syndrome - Therapeutics Assessment
Assessment by Monotherapy Products
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Drug Profiles
4-WF - Drug Profile
Product Description
Mechanism of Action
R&D Progress
AEM-28 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
AEM-28-02 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Artpep-2 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Biologics for Acute Coronary Syndrome - Drug Profile
Product Description
Mechanism of Action
R&D Progress
bivalirudin - Drug Profile
Product Description
Mechanism of Action
R&D Progress
cangrelor - Drug Profile
Product Description
Mechanism of Action
R&D Progress
COR-2 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
COR-3 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
gevokizumab - Drug Profile
Product Description
Mechanism of Action
R&D Progress
losmapimod - Drug Profile
Product Description
Mechanism of Action
R&D Progress
MDCO-216 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
MEDI-6012 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
MTP-131 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
PC-mAb - Drug Profile
Product Description
Mechanism of Action
R&D Progress
PF-06282999 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
PMC-6 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
PR-15 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
rivaroxaban - Drug Profile
Product Description
Mechanism of Action
R&D Progress
SD-970 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
temanogrel hydrochloride - Drug Profile
Product Description
Mechanism of Action
R&D Progress
VTP-38443 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
ZK-001 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Acute Coronary Syndrome - Recent Pipeline Updates
Acute Coronary Syndrome - Dormant Projects
Acute Coronary Syndrome - Discontinued Products
Acute Coronary Syndrome - Product Development Milestones
Featured News & Press Releases
May 11, 2015: Xarelto Bleeding Lawsuit Judge Orders the Selection of Cases for Discovery, Reports Xarelto Lawsuit Funding Firm, Fair Rate Funding
Mar 15, 2015: Stealth BioTherapeutics Announces EMBRACE Results: A Phase 2 Clinical Study of Bendavia in Acute Coronary Syndrome
Oct 22, 2014: NICE draft guidance recommends rivaroxaban (Xarelto) to prevent blood clots in people who have had a heart attack
Sep 02, 2014: Capstone Therapeutics Announces Phase 1a Results for AEM-28 Showing Safety and Biomarker Efficacy Signals
Aug 29, 2014: Janssen Expands EXPLORER Global Cardiovascular Research Program to Evaluate the Role of XARELTO in Addressing Critical Medical Needs
Jun 05, 2014: GSK announces start of phase III cardiovascular outcomes study with losmapimod in patients with acute coronary syndrome
Jan 16, 2014: FDA Advisory Committee Recommends Against Approval of the Use of Oral Anticoagulant XARELTO to Reduce the Risk of Thrombotic Cardiovascular Events in Patients with Acute Coronary Syndrome
Oct 07, 2013: Regulatory Update on Bayer’s Xarelto (Rivaroxaban) 2.5 mg in ACS Indication
Sep 03, 2013: Totality of Data From Three Phase III Trials of The Medicines Company's Intravenous Cangrelor Presented and Published
Jun 28, 2013: FDA Issues Complete Response Letter for XARELTO to Reduce the Risk of Stent Thrombosis in Patients with Acute Coronary Syndrome
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer
List of Tables
Number of Products under Development for Acute Coronary Syndrome, H1 2015
Number of Products under Development for Acute Coronary Syndrome - Comparative Analysis, H1 2015
Number of Products under Development by Companies, H1 2015
Number of Products under Development by Companies, H1 2015 (Contd..1)
Comparative Analysis by Late Stage Development, H1 2015
Comparative Analysis by Clinical Stage Development, H1 2015
Comparative Analysis by Early Stage Development, H1 2015
Products under Development by Companies, H1 2015
Products under Development by Companies, H1 2015 (Contd..1)
Acute Coronary Syndrome - Pipeline by advanceCor GmbH, H1 2015
Acute Coronary Syndrome - Pipeline by Arena Pharmaceuticals, Inc., H1 2015
Acute Coronary Syndrome - Pipeline by Artery Therapeutics, Inc., H1 2015
Acute Coronary Syndrome - Pipeline by AstraZeneca PLC, H1 2015
Acute Coronary Syndrome - Pipeline by Athera Biotechnologies AB, H1 2015
Acute Coronary Syndrome - Pipeline by Auspex Pharmaceuticals, Inc., H1 2015
Acute Coronary Syndrome - Pipeline by Bayer AG, H1 2015
Acute Coronary Syndrome - Pipeline by Esperion Therapeutics, Inc., H1 2015
Acute Coronary Syndrome - Pipeline by GlaxoSmithKline Plc, H1 2015
Acute Coronary Syndrome - Pipeline by Lee's Pharmaceutical Holdings Limited, H1 2015
Acute Coronary Syndrome - Pipeline by MedImmune, LLC, H1 2015
Acute Coronary Syndrome - Pipeline by Pfizer Inc., H1 2015
Acute Coronary Syndrome - Pipeline by The Medicines Company, H1 2015
Acute Coronary Syndrome - Pipeline by Vitae Pharmaceuticals, Inc., H1 2015
Acute Coronary Syndrome - Pipeline by XOMA Corporation, H1 2015
Assessment by Monotherapy Products, H1 2015
Number of Products by Stage and Target, H1 2015
Number of Products by Stage and Mechanism of Action, H1 2015
Number of Products by Stage and Route of Administration, H1 2015
Number of Products by Stage and Molecule Type, H1 2015
Acute Coronary Syndrome Therapeutics - Recent Pipeline Updates, H1 2015
Acute Coronary Syndrome - Dormant Projects, H1 2015
Acute Coronary Syndrome - Dormant Projects (Contd..1), H1 2015
Acute Coronary Syndrome - Dormant Projects (Contd..2), H1 2015
Acute Coronary Syndrome - Discontinued Products, H1 2015
Acute Coronary Syndrome - Discontinued Products (Contd..1), H1 2015
List of Figures
Number of Products under Development for Acute Coronary Syndrome, H1 2015
Number of Products under Development for Acute Coronary Syndrome - Comparative Analysis, H1 2015
Number of Products under Development by Companies, H1 2015
Comparative Analysis by Late Stage Development, H1 2015
Comparative Analysis by Clinical Stage Development, H1 2015
Assessment by Monotherapy Products, H1 2015
Number of Products by Top 10 Targets, H1 2015
Number of Products by Stage and Top 10 Targets, H1 2015
Number of Products by Top 10 Mechanism of Actions, H1 2015
Number of Products by Stage and Top 10 Mechanism of Actions, H1 2015
Number of Products by Top 10 Routes of Administration, H1 2015
Number of Products by Stage and Top 10 Routes of Administration, H1 2015
Number of Products by Top 10 Molecule Types, H1 2015
Number of Products by Stage and Top 10 Molecule Types, H1 2015

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook

Share this report